{"filing":{"accession_number":"0001104659-26-089436","cik":"0001720893","ticker":"BTAI","company_name":"BioXcel Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-07-31","primary_document":"tm2622012d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926089436/tm2622012d1_8k.htm"},"events":[{"id":23017,"run_id":20837,"accession_number":"0001104659-26-089436","anchor_item_number":"1.01","event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The Eleventh Amendment reflects a series of covenant modifications and payment deferrals on the Company's credit facility, signaling financial distress. The reduction of the minimum liquidity covenant from $7.5 million to $6.25 million, combined with the deferral of a $9+ million principal payment originally due June 30, 2026 (now due August 31, 2026), and the requirement to enter into a capital transaction or debt repayment agreement by August 10, 2026, all indicate the Company is in technical default or near-default on its existing obligations. While the filing is styled as an amendment agreement rather than a breach notice, the substance—repeated deferrals, covenant relaxations, and lender-imposed transaction deadlines—reflects a triggering event that materially increases financial obligations and signals covenant stress.","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23153,"accession_number":"0001104659-26-089436","item_number":"1.01","item_title":null,"event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Eleventh Amendment reflects a series of covenant modifications and payment deferrals on the Company's credit facility, signaling financial distress. The reduction of the minimum liquidity covenant from $7.5 million to $6.25 million, combined with the deferral of a $9+ million principal payment originally due June 30, 2026 (now due August 31, 2026), and the requirement to enter into a capital transaction or debt repayment agreement by August 10, 2026, all indicate the Company is in technical default or near-default on its existing obligations. While the filing is styled as an amendment agreement rather than a breach notice, the substance—repeated deferrals, covenant relaxations, and lender-imposed transaction deadlines—reflects a triggering event that materially increases financial obligations and signals covenant stress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T11:01:57.846147+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23153,"accession_number":"0001104659-26-089436","item_number":"1.01","item_title":null,"event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Eleventh Amendment reflects a series of covenant modifications and payment deferrals on the Company's credit facility, signaling financial distress. The reduction of the minimum liquidity covenant from $7.5 million to $6.25 million, combined with the deferral of a $9+ million principal payment originally due June 30, 2026 (now due August 31, 2026), and the requirement to enter into a capital transaction or debt repayment agreement by August 10, 2026, all indicate the Company is in technical default or near-default on its existing obligations. While the filing is styled as an amendment agreement rather than a breach notice, the substance—repeated deferrals, covenant relaxations, and lender-imposed transaction deadlines—reflects a triggering event that materially increases financial obligations and signals covenant stress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T11:01:57.846147+00:00","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-08-03"}]}